Genetic Risk Assessment in Myeloproliferative Neoplasms

Mayo Clinic Proceedings

Volumn 92, Issue 8, 2017, Pages 1283-1290

  Tefferi, Ayalew ^a   Vannucchi, Alessandro Maria ^b  

^a MAYO CLINIC   (United States)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLEEDING; CANCER PROGNOSIS; CHROMOSOME ABERRATION; CYTOGENETICS; DISEASE COURSE; GENE MUTATION; GENETIC RISK; HUMAN; KARYOTYPE; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; THROMBOCYTHEMIA; THROMBOSIS; GENETICS; MORTALITY; MUTATION; MYELOPROLIFERATIVE DISORDERS; PHENOTYPE; PROGNOSIS;

JAK2 PROTEIN, HUMAN; JANUS KINASE 2;

HUMANS; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS; PHENOTYPE; POLYCYTHEMIA VERA; PROGNOSIS; RISK ASSESSMENT; THROMBOCYTHEMIA, ESSENTIAL;

EID: 85027988327     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2017.06.002     Document Type: Review

References (61)

1. Arber, D.A., Orazi, A., Hasserjian, R., et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:20 (2016), 2391–2405.
2. Barbui, T., Thiele, J., Vannucchi, A.M., Tefferi, A., Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer J, 5, 2015, e337.
3. Tefferi, A., Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 24:6 (2010), 1128–1138.
4. Vannucchi, A.M., Rotunno, G., Bartalucci, N., et al. Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. Leukemia 28:9 (2014), 1811–1818.
5. Tefferi, A., Barbui, T., Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 92:1 (2017), 94–108.
6. Gangat, N., Wolanskyj, A.P., Schwager, S., Tefferi, A., Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. Eur J Haematol 82:5 (2009), 350–353.
7. Tefferi, A., Pregnancy and thrombocythemia. Am J Hematol 57:2 (1998), 181–182.
8. Tefferi, A., Guglielmelli, P., Larson, D.R., et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 124:16 (2014), 2507–2513 quiz 2615.
9. Vannucchi, A.M., Antonioli, E., Guglielmelli, P., Pardanani, A., Tefferi, A., Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 22:7 (2008), 1299–1307.
10. Finazzi, M.C., Carobbio, A., Cervantes, F., et al. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis. Leukemia 29:5 (2015), 1209–1210.
11. Barraco, D., Elala, Y.C., Lasho, T.L., et al. Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations. Blood Cancer J, 6, 2016, e416.
12. Tefferi, A., Finke, C.M., Lasho, T.L., et al. U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. Leukemia 28:2 (2014), 431–433.
13. Cerquozzi, S., Tefferi, A., Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J, 5, 2015, e366.
14. Pardanani, A., Lasho, T.L., Finke, C., Hanson, C.A., Tefferi, A., Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 21:9 (2007), 1960–1963.
15. Tefferi, A., Lasho, T.L., Guglielmelli, P., et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv 1:1 (2016), 21–30.
16. Tefferi, A., Lasho, T.L., Finke, C.M., et al. Targeted deep sequencing in primary myelofibrosis. Blood Adv 1 (2016), 105–111.
17. Wassie, E., Finke, C., Gangat, N., et al. A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients. Br J Haematol 169:1 (2015), 71–76.
18. Gangat, N., Strand, J., Lasho, T.L., et al. Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. Eur J Haematol 80:3 (2008), 197–200.
19. Gangat, N., Tefferi, A., Thanarajasingam, G., et al. Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. Eur J Haematol 83:1 (2009), 17–21.
20. Tefferi, A., Rumi, E., Finazzi, G., et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27:9 (2013), 1874–1881.
21. Passamonti, F., Thiele, J., Girodon, F., et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 120:6 (2012), 1197–1201.
22. Barbui, T., Thiele, J., Passamonti, F., et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 29:23 (2011), 3179–3184.
23. Gangat, N., Wolanskyj, A.P., McClure, R.F., et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 21:2 (2007), 270–276.
24. Haider, M., Elala, Y.C., Gangat, N., Hanson, C.A., Tefferi, A., MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia. Blood Cancer J, 6(10), 2016, e487.
25. Elala, Y.C., Lasho, T.L., Gangat, N., et al. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. Am J Hematol 91:5 (2016), 503–506.
26. Tefferi, A., Wassie, E.A., Lasho, T.L., et al. Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia 28:12 (2014), 2300–2303.
27. Haider, M., Gangat, N., Lasho, T., et al. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. Am J Hematol 91:4 (2016), 390–394.
28. Haider, M., Gangat, N., Hanson, C., Tefferi, A., Splenomegaly and thrombosis risk in essential thrombocythemia: the Mayo Clinic experience. Am J Hematol 91:5 (2016), E296–E297.
29. Barbui, T., Vannucchi, A.M., Buxhofer-Ausch, V., et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J, 5, 2015, e369.
30. Carobbio, A., Thiele, J., Passamonti, F., et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 117:22 (2011), 5857–5859.
31. Finazzi, G., Carobbio, A., Guglielmelli, P., et al. Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood 124:16 (2014), 2611–2612.
32. Rotunno, G., Pacilli, A., Artusi, V., et al. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. Am J Hematol 91:7 (2016), 681–686.
33. Passamonti, F., Mora, B., Giorgino, T., et al. Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients. Leukemia 31:4 (2017), 970–973.
34. Cerquozzi, S., Barraco, D., Hanson, C.A., et al. Abnormal karyotype and prognosis in polycythemia vera: a single center experience in 239 informative cases. Blood, 128, 2016, 3115.
35. Broséus, J., Park, J.H., Carillo, S., Hermouet, S., Girodon, F., Presence of calreticulin mutations in JAK2-negative polycythemia vera. Blood 124:26 (2014), 3964–3966.
36. Pardanani, A., Lasho, T.L., Finke, C.M., Tefferi, A., Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis. Am J Hematol 86:8 (2011), 701–702.
37. Passamonti, F., Elena, C., Schnittger, S., et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 117:10 (2011), 2813–2816.
38. Passamonti, F., Rumi, E., Pietra, D., et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 24:9 (2010), 1574–1579.
39. Cervantes, F., Dupriez, B., Pereira, A., et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113:13 (2009), 2895–2901.
40. Passamonti, F., Cervantes, F., Vannucchi, A.M., et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115:9 (2010), 1703–1708.
41. Gangat, N., Caramazza, D., Vaidya, R., et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29:4 (2011), 392–397.
42. Hussein, K., Pardanani, A.D., Van Dyke, D.L., Hanson, C.A., Tefferi, A., International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood 115:3 (2010), 496–499.
43. Caramazza, D., Begna, K.H., Gangat, N., et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia 25:1 (2011), 82–88.
44. Tefferi, A., Jimma, T., Gangat, N., et al. Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. Blood 118:17 (2011), 4595–4598.
45. Tefferi, A., Wassie, E.A., Begna, K., et al. Revised cytogenetic risk stratification in primary myelofibrosis: a Mayo Clinic study of 903 patients. Blood, 124, 2014, 631.
46. Tefferi, A., Lasho, T.L., Tischer, A., et al. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood 124:15 (2014), 2465–2466.
47. Tefferi, A., Guglielmelli, P., Lasho, T.L., et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia 28:7 (2014), 1494–1500.
48. Tefferi, A., Lasho, T.L., Finke, C.M., et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 28:7 (2014), 1472–1477.
49. Guglielmelli, P., Rotunno, G., Fanelli, T., et al. Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis. Blood Cancer J, 5, 2015, e360.
50. Guglielmelli, P., Lasho, T.L., Rotunno, G., et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia 28:9 (2014), 1804–1810.
51. Guglielmelli, P., Biamonte, F., Rotunno, G., et al. COMFORT-II Investigators, Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood 123:14 (2014), 2157–2160.
52. Vannucchi, A.M., Lasho, T.L., Guglielmelli, P., et al. Mutations and prognosis in primary myelofibrosis. Leukemia 27:9 (2013), 1861–1869.
53. Guglielmelli, P., Biamonte, F., Score, J., et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 118:19 (2011), 5227–5234.
54. Tefferi, A., Lasho, T.L., Abdel-Wahab, O., et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 24:7 (2010), 1302–1309.
55. Tefferi, A., Jimma, T., Sulai, N.H., et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 26:3 (2012), 475–480.
56. Lasho, T.L., Jimma, T., Finke, C.M., et al. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood 120:20 (2012), 4168–4171.
57. Tefferi, A., Lasho, T.L., Patnaik, M.M., et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia 24:1 (2010), 105–109.
58. Tefferi, A., Lasho, T.L., Huang, J., et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 22:4 (2008), 756–761.
59. Guglielmelli, P., Barosi, G., Specchia, G., et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 114:8 (2009), 1477–1483.
60. Pardanani, A., Lasho, T.L., Finke, C.M., et al. Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. J Clin Oncol 30:10 (2012), 1087–1094.
61. Tefferi, A., Vaidya, R., Caramazza, D., Finke, C., Lasho, T., Pardanani, A., Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 29:10 (2011), 1356–1363.